ARID1A and ovarian clear cell cancer: Immunohistochemical analysis of 53 ovarian clear cell carcinoma (OCCC) patient samples was the first report demonstrating that low levels of ARID1A protein can serve as a marker of poor outcome in OCCC patients, whereby out of the 53 patients, eight with low ARID1A expression had shorter progression-free survival than those with high expression (p = 0.044, log-rank test) [67].